NLS PHARMACEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1367 USD | +3.25% |
|
+3.01% | -76.83% |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 16.37 | 42.83 |
| Enterprise Value (EV) 1 | 10.94 | 33.88 |
| P/E ratio | -1.11 x | -1.54 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -923,135 x | -2,189,945 x |
| EV / FCF | -1,026,095 x | -3,899,619 x |
| FCF Yield | -0% | -0% |
| Price to Book | 30.2 x | 12.8 x |
| Nbr of stocks (in thousands) | 14,749 | 33,201 |
| Reference price 2 | 1.110 | 1.290 |
| Announcement Date | 3/24/22 | 5/5/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | - | -11.85 | -15.47 |
| EBIT 1 | -5.767 | -3.449 | -4.197 | -2.299 | -11.86 | -15.48 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.657 | -5.147 | -5.447 | -2.861 | -11.95 | -16.5 |
| Net income 1 | -6.657 | -5.147 | -5.447 | -2.861 | -11.95 | -16.5 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -1.099 | -0.8248 | -0.7964 | -0.4111 | -1.004 | -0.8381 |
| Free Cash Flow | - | -1.019 | -0.82 | 0.6351 | -10.66 | -8.688 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/28/20 | 8/31/20 | 5/14/21 | 3/24/22 | 5/5/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -1.218 | -8.688 | -6.794 | -7.549 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -8.641 | -7.855 | -7.613 |
| Net income 1 | -1.232 | -1.629 | -8.641 | -7.855 | -7.613 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.1800 | -0.2300 | -0.5400 | -0.3000 | -0.2000 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 10/19/20 | 5/14/21 | 10/11/22 | 5/5/23 | 12/6/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 6.68 | 7.09 | 0.62 | 1.99 | - | - |
| Net Cash position 1 | - | - | - | - | 5.43 | 8.95 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -1.02 | -0.82 | 0.64 | -10.7 | -8.69 |
| ROE (net income / shareholders' equity) | - | 62.3% | 72.7% | 37.8% | 283% | -863% |
| ROA (Net income/ Total Assets) | - | -177% | -623% | -151% | -213% | -129% |
| Assets 1 | - | 2.906 | 0.8743 | 1.9 | 5.621 | 12.82 |
| Book Value Per Share 2 | -1.270 | -1.270 | -0.8900 | -1.290 | 0.0400 | 0.1000 |
| Cash Flow per Share 2 | 0.3600 | 0 | 0.0300 | 0.0100 | 0.3700 | 0.2800 |
| Capex | - | - | - | - | 0.04 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/28/20 | 8/31/20 | 5/14/21 | 3/24/22 | 5/5/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -76.83% | 6.44M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NLSP Stock
- Financials NLS Pharmaceutics Ltd.
